Your institution may have access to this item. Find your institution then sign in to continue.
Title
Inadequately met needs.
Abstract
The author asserts that U.S. innovative drug development faces challenges when it comes to chronic diseases. Data from the IMS Institute for Healthcare Informatics show that overall drug spending in the country posted a 1% year-on-year increase for 2009-2010. He adds that the trend in which consumers are opting for cheaper, older or generic drugs is prevalent for drugs intended for chronic diseases. He recommends a mechanism for innovative drug development as well as an orphan drug legislation.